An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-na ve EGFR-mutant Locally Advanced or Metastatic NSCLC

Brief description of study

The purpose of this study is to find out whether the addition of ramucirumab to osimertinib is better at controlling EGFR lung cancer than just osimertinib itself. The combination of the two medications is investigational. Al investigational medication or drug is one that has not been approved by the U.S. Food & Drug Administration (FDA).




If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.